Optimal amount of monocyte chemoattractant protein-1 enhances antitumor effects of suicide gene therapy against hepatocellular carcinoma by M1 macrophage activation.

Tomoya Tsuchiyama, Yasunari Nakamoto, Yoshio Sakai, Naofumi Mukaida, Shuichi Kaneko
Author Information
  1. Tomoya Tsuchiyama: Disease Control and Homeostasis, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan.

Abstract

Suicide gene therapy combined with chemokines provides significant antitumor efficacy. Coexpression of suicide gene and monocyte chemoattractant protein-1 (MCP-1) increases antitumor effects in murine models of hepatocellular carcinoma (HCC) and colon cancer. However, it is unclear whether the doses administered achieved the maximum antitumor effects. We evaluated antitumor effects of various amounts of recombinant adenovirus vector (rAd) expressing MCP-1 in the presence of a suicide gene in a murine model of HCC. HCC cells were transplanted subcutaneously into BALB/c nude mice, and transduced with a fixed amount of Ad-tk harboring the suicide gene, HSV-tk, and various doses of Ad-MCP1 harboring MCP-1 (ratios of 1:1, 0.1:1, and 0.01:1 relative to Ad-tk). Growth of primary tumors was suppressed when treated with Ad-tk plus Ad-MCP1 (1:1 and 1:0.1) as compared with Ad-tk alone. The antitumor effects against tumor rechallenge tended to be high in the Ad-tk plus Ad-MCP1 group (1:0.1). The effects were dependent on production of Th1 type-cytokines. Delivery of an optimal amount of rAd expressing MCP-1 enhanced the antitumor effects of suicide gene therapy against HCC by M1 macrophage activation, suggesting that this is a plausible form of cancer gene therapy to prevent HCC progression and recurrence.

References

  1. Biochem Biophys Res Commun. 1998 Mar 17;244(2):455-62 [PMID: 9514856]
  2. Immunol Today. 1992 Jul;13(7):265-70 [PMID: 1388654]
  3. Int J Cancer. 1997 Apr 10;71(2):267-74 [PMID: 9139853]
  4. Cancer Gene Ther. 2003 Apr;10(4):260-9 [PMID: 12679798]
  5. J Immunol. 2000 Feb 15;164(4):1699-704 [PMID: 10657613]
  6. Blood. 2006 Mar 1;107(5):2112-22 [PMID: 16269622]
  7. Exp Hematol. 1996 Jun;24(7):829-38 [PMID: 8647234]
  8. Gene Ther. 1997 Nov;4(11):1160-6 [PMID: 9425438]
  9. Cancer Res. 2000 Dec 15;60(24):7002-7 [PMID: 11156403]
  10. J Immunol. 2001 Jun 1;166(11):6483-90 [PMID: 11359798]
  11. Cancer Res. 1999 Oct 1;59(19):4906-11 [PMID: 10519403]
  12. Anticancer Res. 2000 May-Jun;20(3A):1359-65 [PMID: 10928044]
  13. Gene Ther. 1996 Nov;3(11):957-64 [PMID: 8940635]
  14. Proc Natl Acad Sci U S A. 1994 May 10;91(10):4348-52 [PMID: 8183911]
  15. Mol Cell Biol. 1991 Jun;11(6):3125-31 [PMID: 2038321]
  16. Immunopharmacology. 1983 Oct;6(3):177-89 [PMID: 6629737]
  17. Trends Immunol. 2004 Dec;25(12):677-86 [PMID: 15530839]
  18. Curr Opin Immunol. 1998 Jun;10(3):259-64 [PMID: 9638361]
  19. J Virol Methods. 2001 Mar;92(1):5-17 [PMID: 11164913]
  20. Clin Cancer Res. 2000 Aug;6(8):3282-9 [PMID: 10955814]
  21. Trends Immunol. 2002 Nov;23(11):549-55 [PMID: 12401408]
  22. Mol Ther. 2000 Apr;1(4):376-82 [PMID: 10933956]
  23. Immunol Today. 1996 May;17(5):214-7 [PMID: 8991382]
  24. Annu Rev Immunol. 2001;19:683-765 [PMID: 11244051]
  25. Cancer Gene Ther. 2006 Apr;13(4):357-66 [PMID: 16224495]
  26. Cancer Gene Ther. 2001 Oct;8(10):695-704 [PMID: 11687892]
  27. J Gastroenterol. 2006 Feb;41(2):100-6 [PMID: 16568368]
  28. J Exp Med. 1989 Apr 1;169(4):1485-90 [PMID: 2926331]
  29. J Immunol. 2007 Jan 1;178(1):574-83 [PMID: 17182598]

MeSH Term

Adenoviridae
Animals
Carcinoma, Hepatocellular
Cell Line, Tumor
Chemokine CCL2
Disease Models, Animal
Enzyme-Linked Immunosorbent Assay
Genes, Transgenic, Suicide
Genetic Therapy
Genetic Vectors
Humans
Immunohistochemistry
Liver Neoplasms, Experimental
Macrophage Activation
Macrophages, Peritoneal
Male
Mice
Mice, Nude
Xenograft Model Antitumor Assays

Chemicals

Chemokine CCL2

Word Cloud

Created with Highcharts 10.0.0geneantitumoreffectssuicideHCCAd-tktherapyMCP-1amountAd-MCP11:1monocytechemoattractantprotein-1murinehepatocellularcarcinomacancerdosesvariousrAdexpressingharboring0plus1:01M1macrophageactivationSuicidecombinedchemokinesprovidessignificantefficacyCoexpressionincreasesmodelscolonHoweverunclearwhetheradministeredachievedmaximumevaluatedamountsrecombinantadenovirusvectorpresencemodelcellstransplantedsubcutaneouslyBALB/cnudemicetransducedfixedHSV-tkratios01:1relativeGrowthprimarytumorssuppressedtreatedcomparedalonetumorrechallengetendedhighgroupdependentproductionTh1type-cytokinesDeliveryoptimalenhancedsuggestingplausibleformpreventprogressionrecurrenceOptimalenhances

Similar Articles

Cited By